Alcon's Late-Stage Pipeline Set To Drive Revenue Growth Next Year -- Market Talk

Dow Jones

2024-12-17

1505 GMT - Alcon's pipeline of products in the late stage of development is the most solid since its spinoff from Swiss pharma giant Novartis, and is set to drive revenue growth next year, Needham analysts say. The Swiss-American medical device company has eight planned product launches in 2025, the analyst write in a note. Among them, contact lenses PanOptix Pro and Precision 7 will be watched keenly by investors, they say. Alcon's current valuation, significantly below historical averages, presents an attractive entry point. Commercial investment risks and foreign currency headwinds are already factored in, they add. Alcon shares rise 0.34% to 75.86 Swiss francs. (helena.smolak@wsj.com)

(END) Dow Jones Newswires

December 17, 2024 10:05 ET (15:05 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2492966450"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492966450\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2492966450?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-17 23:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492966450","market":"other","top_or_hot":-1,"title":"Alcon's Late-Stage Pipeline Set To Drive Revenue Growth Next Year -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1505 GMT - Alcon's pipeline of products in the late stage of development is the most solid since its spinoff from Swiss pharma giant Novartis, and is set to drive revenue growth next year, Needham analysts say. The Swiss-American medical device company has eight planned product launches in 2025, the analyst write in a note. Among them, contact lenses PanOptix Pro and Precision 7 will be watched keenly by investors, they say. Alcon's current valuation, significantly below historical averages, presents an attractive entry point. Commercial investment risks and foreign currency headwinds are already factored in, they add. Alcon shares rise 0.34% to 75.86 Swiss francs. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2024 10:05 ET (15:05 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alcon's Late-Stage Pipeline Set To Drive Revenue Growth Next Year -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlcon's Late-Stage Pipeline Set To Drive Revenue Growth Next Year -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-17 23:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1505 GMT - Alcon's pipeline of products in the late stage of development is the most solid since its spinoff from Swiss pharma giant Novartis, and is set to drive revenue growth next year, Needham analysts say. The Swiss-American medical device company has eight planned product launches in 2025, the analyst write in a note. Among them, contact lenses PanOptix Pro and Precision 7 will be watched keenly by investors, they say. Alcon's current valuation, significantly below historical averages, presents an attractive entry point. Commercial investment risks and foreign currency headwinds are already factored in, they add. Alcon shares rise 0.34% to 75.86 Swiss francs. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2024 10:05 ET (15:05 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALC","symbol_name":"爱尔康","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492966450","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492966450","pubTimestamp":1734447900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1505 GMT - Alcon's pipeline of products in the late stage of development is the most solid since its spinoff from Swiss pharma giant Novartis, and is set to drive revenue growth next year, Needham analysts say. The Swiss-American medical device company has eight planned product launches in 2025, the analyst write in a note. Among them, contact lenses PanOptix Pro and Precision 7 will be watched keenly by investors, they say. Alcon's current valuation, significantly below historical averages, presents an attractive entry point. Commercial investment risks and foreign currency headwinds are already factored in, they add. Alcon shares rise 0.34% to 75.86 Swiss francs. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ALC":"爱尔康","SSI":"Stage Stores Inc"},"translate_title":"爱尔康的后期产品线将推动明年收入增长——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALC":0.9,"SSI":1},"content_text":"1505 GMT - Alcon's pipeline of products in the late stage of development is the most solid since its spinoff from Swiss pharma giant Novartis, and is set to drive revenue growth next year, Needham analysts say. The Swiss-American medical device company has eight planned product launches in 2025, the analyst write in a note. Among them, contact lenses PanOptix Pro and Precision 7 will be watched keenly by investors, they say. Alcon's current valuation, significantly below historical averages, presents an attractive entry point. Commercial investment risks and foreign currency headwinds are already factored in, they add. Alcon shares rise 0.34% to 75.86 Swiss francs. (helena.smolak@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2024 10:05 ET (15:05 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}